Clinical Trials
Alumis's TYK2 inhibitor envudeucitinib missed primary and secondary endpoints in a Phase IIb study of systemic lupus erythematosus, but the high interferon gene signature subgroup showed a "robust" response. The company still plans to move forward and will discuss the Phase III trial path with regulators. Shares plunged nearly 55% after the announcement.
At the 2026 European Society of Cardiology (ESC) Annual Meeting, several major pharmaceutical and biotechnology companies presented detailed study data on drugs for various heart diseases. This article reviews three closely watched clinical data sets and their impact on investors and analysts: detailed data from Cytokinetics' Myqorzo Phase III study in non-obstructive hypertrophic cardiomyopathy showed robust efficacy, but the disclosure of specific heart failure events led to a stock price decline of over 7%; Arrowhead's plozasiran demonstrated comparable efficacy and potentially better safety versus Ionis' Tryngolza in two Phase III studies for severe hypertriglyceridemia, with a marketing application expected by year-end; and the detailed analysis following the Phase III failure of eplontersen, developed by AstraZeneca and Ionis, for transthyretin amyloid cardiomyopathy, sparked renewed discussion on the positioning of existing therapies and the prospects of Alnylam's investigational drug.
Spyre Therapeutics announced results from a Phase 2 trial of SPY072 in rheumatoid arthritis, where the drug failed to meet the company's predefined development threshold, prompting a shift to other autoimmune indications. Shares dropped 13% in response, with a market value loss exceeding $1 billion.